title: Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes.
abstract: There is little information on the effects of treatment with vasoconstrictors plus albumin in patients with type 2 hepatorenal syndrome (HRS), particularly those awaiting liver transplantation (LT). This study reports the effects of treatment of type 2 HRS in patients on the waiting list for LT. We included 56 patients with type 2 HRS who were awaiting LT. Out of these 56 patients, 31 were treated with terlipressin and albumin. Nineteen (61%) of these 31 patients had response to therapy, and 11 of them relapsed after treatment withdrawal. There were no differences in mortality on the waiting list between responders and nonresponders. Among the 46 (82%) patients who underwent transplantation, 15 underwent transplantation with reversal of type 2 HRS, whereas the remaining 31 underwent transplantation with type 2 HRS. There were no significant differences in serum creatinine or estimated glomerular filtration rate between the 2 cohorts of patients at 3, 6, and 12 months after transplantation. There were no significant differences regarding development of acute kidney injury, need for renal replacement therapy, frequency of chronic kidney disease 1 year after transplant, length of hospitalization, and survival. In conclusion, treatment of patients with type 2 HRS with terlipressin and albumin does not appear to have beneficial effects either in pretransplantation or in posttransplantation outcomes.
authors.affiliation: Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Catalunya, Spain.|Institut d'Investigacions Biomèdiques August-Pi-Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Catalonia, Spain.|Instituto Reina Sofía de Investigación Nefrológica (IRSIN).
authors.forename: Ezequiel
authors.initials: E
authors.lastname: Rodriguez
authors.affiliation: Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Catalunya, Spain.|Institut d'Investigacions Biomèdiques August-Pi-Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Catalonia, Spain.|Instituto Reina Sofía de Investigación Nefrológica (IRSIN).
authors.forename: Gustavo
authors.initials: G
authors.lastname: Henrique Pereira
authors.affiliation: Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Catalunya, Spain.|Institut d'Investigacions Biomèdiques August-Pi-Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Catalonia, Spain.|Instituto Reina Sofía de Investigación Nefrológica (IRSIN).
authors.forename: Elsa
authors.initials: E
authors.lastname: Solà
authors.affiliation: Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Catalunya, Spain.|Institut d'Investigacions Biomèdiques August-Pi-Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Catalonia, Spain.|Instituto Reina Sofía de Investigación Nefrológica (IRSIN).
authors.forename: Chiara
authors.initials: C
authors.lastname: Elia
authors.affiliation: Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Catalunya, Spain.|Institut d'Investigacions Biomèdiques August-Pi-Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Catalonia, Spain.|Instituto Reina Sofía de Investigación Nefrológica (IRSIN).
authors.forename: Rogelio
authors.initials: R
authors.lastname: Barreto
authors.affiliation: Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Catalunya, Spain.|Institut d'Investigacions Biomèdiques August-Pi-Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Catalonia, Spain.|Instituto Reina Sofía de Investigación Nefrológica (IRSIN).
authors.forename: Elisa
authors.initials: E
authors.lastname: Pose
authors.affiliation: Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Catalunya, Spain.|Institut d'Investigacions Biomèdiques August-Pi-Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Catalonia, Spain.
authors.forename: Jordi
authors.initials: J
authors.lastname: Colmenero
authors.affiliation: Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Catalunya, Spain.|Institut d'Investigacions Biomèdiques August-Pi-Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Catalonia, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Fernandez
authors.affiliation: Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Catalunya, Spain.|Institut d'Investigacions Biomèdiques August-Pi-Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Catalonia, Spain.
authors.forename: Miquel
authors.initials: M
authors.lastname: Navasa
authors.affiliation: Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Catalunya, Spain.|Institut d'Investigacions Biomèdiques August-Pi-Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Catalonia, Spain.|Instituto Reina Sofía de Investigación Nefrológica (IRSIN).
authors.forename: Vicente
authors.initials: V
authors.lastname: Arroyo
authors.affiliation: Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Catalunya, Spain.|Institut d'Investigacions Biomèdiques August-Pi-Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Catalonia, Spain.
authors.forename: Pere
authors.initials: P
authors.lastname: Ginès
mesh_terms: D000418:Albumins / Q000008:administration & dosage*; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006530:Hepatorenal Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007275:Injections, Intravenous; D007677:Kidney Function Tests; D016031:Liver Transplantation; D008236:Lypressin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012720:Severity of Illness Index; D013030:Spain / Q000453:epidemiology; D015996:Survival Rate / Q000639:trends; D000077585:Terlipressin; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000008:administration & dosage; D014850:Waiting Lists; D057832:Watchful Waiting / Q000379:methods*
chemical_list: D000418:Albumins; D014662:Vasoconstrictor Agents; D008236:Lypressin; D000077585:Terlipressin; D003404:Creatinine